^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    B001

    i
    Other names: B001, B-001
    Associations

    News

    Trials
    Company:
    Shanghai Pharma
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) (clinicaltrials.gov)
    P2/3, N=132, Not yet recruiting, Shanghai Jiaolian Drug Research and Development Co., Ltd
    New P2/3 trial
    |
    B001
    7ms
    Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) (clinicaltrials.gov)
    P1, N=45, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial primary completion date: Apr 2024 --> Dec 2024
    Trial primary completion date
    |
    B001
    12ms
    Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) (clinicaltrials.gov)
    P1, N=45, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
    Trial completion date • Trial primary completion date
    |
    B001
    3years
    B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=30, Completed, Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting --> Completed
    Clinical • Trial completion
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    B001